SNOA

Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.

Wall Street analysts forecast SNOA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNOA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sonoma Pharmaceuticals Inc revenue for the last quarter amounts to 5.60M USD, increased 56.58 % YoY.

Sonoma Pharmaceuticals Inc. EPS for the last quarter amounts to -0.32 USD, decreased -45.76 % YoY.

Sonoma Pharmaceuticals Inc (SNOA) has 168 emplpoyees as of December 16 2025.

Today SNOA has the market capitalization of 5.80M USD.